SCHEMBL16936478

SCHEMBL16936478

N#Cc1c(-c2ccc(CO)cc2)ccnc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.49
ALDH1A1 P00352 5/20 0.49
LMNA P02545 3/20 0.49
TDP1 Q9NUW8 1/20 0.49
L3MBTL1 Q9Y468 3/20 0.43
GAA P10253 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
PDCD1 Q15116 1/20 0.42
CD274 Q9NZQ7 1/20 0.42
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
MKNK1 Q9BUB5 1/20 0.40
MKNK2 Q9HBH9 1/20 0.40
FYN P06241 2/20 0.40
RECQL P46063 1/20 0.40
AR P10275 2/20 0.39
CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1162716 0.85 KDM4E (0.50) KDM4EALDH1A1LMNATDP1L3MBTL1
SCHEMBL1702791 0.82 KDM4E (0.50) KDM4EALDH1A1LMNATDP1L3MBTL1
SCHEMBL15638514 0.82 KDM4E (0.61) KDM4EALDH1A1LMNATDP1L3MBTL1
SCHEMBL16936423 0.82 KDM4E (0.54) KDM4EALDH1A1LMNATDP1L3MBTL1
SCHEMBL16681058 0.81 ALDH1A1 (0.59) KDM4EALDH1A1LMNATDP1L3MBTL1
SCHEMBL1162717 0.78 KDM4E (0.61) KDM4EALDH1A1LMNATDP1L3MBTL1
SCHEMBL29986005 0.76 AR (0.37) KDM4EALDH1A1LMNATDP1L3MBTL1
SCHEMBL1703147 0.76 KDM4E (0.45) KDM4EALDH1A1LMNATDP1L3MBTL1
SCHEMBL1162714 0.76 ALDH1A1 (0.65) KDM4EALDH1A1LMNATDP1L3MBTL1
SCHEMBL16936234 0.76 KDM4E (0.48) KDM4EALDH1A1LMNATDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3096754-B1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME (US) 2018-08-29 EP disclosed
US-9708336-B2 Metallo-beta-lactamase inhibitors MERCK SHARP & DOHME CORP. (US) 2017-07-18 US disclosed
EP-3096754-A1 METALLO-BETA-LACTAMASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-11-30 EP disclosed
US-20160333021-A1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-11-17 US disclosed
WO-2015112441-A1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-07-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160333021-A1 METALLO-BETA-LACTAMASE INHIBITORS MGAM, MGAM2, GAA KDM4E 2116/4885ALDH1A1 329/4885LMNA 1585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.